Davis City Pharmacy, Inc., Weatherford, TX

Is Davis City Pharmacy, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location.

Does Davis City Pharmacy, Inc. hold a Texas pharmacy license?

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed.

Has Davis City Pharmacy, Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Aug 5, 2022), 1 state referral letter (Nov 30, 2022) and 1 FMD-145 letter (Nov 30, 2022) for Davis City Pharmacy, Inc. Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Davis City Pharmacy, Inc.
Location
Weatherford, TX
Type as FDA labels it
Not stated
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Nov 30, 2022
FDA Data Dashboard inspections
1 inspection: 1 VAI; 1 published Form 483
Form 483 text on this page
1 Form 483, 5 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Davis City Pharmacy, Inc., with 4 dated actions.

Document
Nov 30, 2022State referral letterReferral Letter to the Texas State Board of Pharmacy Issued 11/30/2022FDA copy (archived)
Nov 30, 2022FMD-145 letterFMD-145 Issued 11/30/2022Not linked by FDA
Aug 5, 2022Untitled letterUntitled Letter Issued 08/05/2022FDA copy (archived)
Feb 18, 2022Form 483483 Issued 02/18/2022FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Davis City Pharmacy Inc., Weatherford, TX (FEI number 3016774626), matched to this page by exact name, city and state. It lists 1 inspection: 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Feb 18, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30167746261162808

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 5 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Feb 15, 2022 to Feb 18, 2022: 5 observations

Firm on the cover
Davis City Pharmacy Inc., 111 Trinity St, Weatherford, TX 76086-3358
FEI number
3016774626
Establishment type on the cover
Producer of Non Sterile Drug Products
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

You produced highly potent drugs without providing adequate containment, segregation, cleaning of work surfaces and cleaning of utensils to prevent cross-contamination.

Specifically,

a) Your firm routinely compounds potent and/or hazardous non-sterile drug products (creams and capsules) containing hormones such as Progesterone or Testosterone on a counter top without procedures/systems in place to ensure containment and proper segregation of potent/hazardous drugs as well as to prevent cross contamination. Approximately <Redacted B4> lots of non-sterile drug products containing Progesterone and approximately <Redacted B4> lots of non-sterile drug products containing Testosterone were produced from 8/15/2021 to 2/16/2022. On 2/15/2022, we observed the non-sterile technician weigh out Testosterone <Redacted B4> Lot <Redacted B4> a potent and potentially hazardous drug substance to prepare a non-sterile compounded cream on an open counter top designated for non-sterile non-hazardous and hazardous compounding activities in the firm's compounding lab. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Unsealed, loose ceiling tiles were observed in your non-sterile "compounding lab".

Specifically,

On 2 /15 /2022, exposed blue wires were observed hanging in plain sight from a loose unsealed ceiling tile of the non-sterile "compounding lab" during the preparation of your non-sterile Testosterone Cream 2%, 20mg, Lot #2002152022 with a beyond use date of 03/15/2022.

Observation 3

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically,

Your firm failed to conduct appropriate tests to determine the identity and strength of each active ingredient in the following non-sterile drug products prior to release and distribution:

• Rx <Redacted B6>: Benzocaine 20%, Lidocaine 10%, Tetracaine 10% Lot #09302021, BUD:10/ 30/ 2021.

Observation 4

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

Your firm failed to establish microbial specifications for your finished non-sterile compounded drug products to assure that it meets the appropriate standards for microbial quality. The firm failed to perform testing/evaluate the following non-sterile drug products for microbial limits and objectionable organisms:

• Benzocaine 20%, Lidocaine 10%, Tetracaine 10%, Lot #09302021, BUD: 10/30/2021 .

• Benzocaine 20%, Lidocaine 10%, Tetracaine 10%, Lot #20101002012022, BUD: 08/01/2022 .

Observation 5

Batch production and control records do not include complete information relating to the production and control of each batch.

Specifically,

Your firm's production records (formula worksheets) for Benzocaine 20%, Lidocaine 10%, Tetracaine 10% cream, Lot #09302021 and Lot #20101002012022 are deficient because t hey do not contain t he following information:

• Order of mixing ingredients

• Step by step instructions

• Procedures to ensure proper blending of particles

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. ...

Read the full 483 (PDF on fda.gov)

State board of pharmacy records

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.